AstraZeneca PLC And Moderna Announce New Collaboration To Co-Develop And Co-Commercialize Immuno-Oncology mRNA Therapeutics

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics™ for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.

Back to news